



Faculty disclosures report

The 2024 COMy Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COMy participants. In doing so, the 2024 COMy Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all of its scientific, educational, and advocacy activities and materials.

Educational Content Development

The 2024 COMy Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The 2024 COMy Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the 2024 COMy Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the 2024 COMy Congress of CME based on the CME providers of the Congress.

All 2024 COMy Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The 2024 COMy Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

2024 COMy Financial Disclosure Codes

Type of affiliation / financial interest	Code
Honorarium	H
Consultant	C
Advisory Boards	A
Research Funding	R
Speakers' Bureau	S
Employee	E
Other	<i>Written as stated on submitted form</i>
Nothing to declare	<i>Written as said statement</i>

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Kenneth Anderson, USA

C Astra Zeneca, Janssen, Pfizer
A Dynamic Cell Therapies, C4 Therapeutics, Next RNA, Oncopeptides, Starton, Window

Nizar Bahlis, Canada

H, A Amgen, BMS, Celgene, Janssen, Genentech, GSK, Pfizer, Sanofi, Takeda
R Pfizer, Janssen



The 10th World Congress on Controversies in Multiple Myeloma (COMy)
May 23-26, 2024 - Paris, France & Online
<https://comylive.cme-congresses.com/>

Eileen Boyle, USA

Nothing to declare

Ceri Bygrave, UK

H Pfizer, Amgen, Takeda, BMS, GSK, Janssen

A Pfizer, GSK, Menarini Stemline

Jill Corre, France

Nothing to declare

Bhagirathbhai Dholaria, USA

H Adaptive, ADC, MJH Bio, Dava Oncology

C Janssen, Gilead, Acrotech

A Janssen

R Janssen, Pfizer, Gilead, Takeda, Adicet, Wugen, MEI, Angiocrine, Poseida

Brian Durie, USA

Nothing to declare

Hermann Einsele, Germany

H,C,A BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis, Roche

R BMS/Celgene, Janssen, Amgen, GSK, Sanofi

Thierry Facon, France

Nothing to declare

Francesca Gay, Italy

H Janssen, Amgen, Sanofi, GSK, AbbVie, Takeda

A Janssen, Amgen, Sanofi, GSK, AbbVie, Takeda, Roche, Pfizer

Irene Ghobrial, USA

C BMS, Novartis, Amgen, Takeda, Sanofi, Janssen, Pfizer, Menarini, The Binding Site, GSK, AbbVie, Adaptive, 10xGenomics, Window, Regeneron, Aptitude Health, Standard Biotech

H,S BMS, Janssen, Menarini, Vor Biopharma, Takeda, Amgen, Janssen, Regeneron, CurioScience

O *Travel to attend meetings:* BMS, Novartis, Amgen, Menarini, Pfizer

Hartmut Goldschmidt, Germany

Nothing to declare

Jean-Luc Harousseau, France

Nothing to declare

Vania Hungria, Brazil

H Amgen, BMS, GSK, Janssen, Regeneron, Sanofi, Takeda

Sigurdur Kristinsson, Iceland

R IMF, Amgen, BMS, Icelandic Centre for Research, ERC, IMS, LLS

Shaji Kumar, USA

H CVS, BD

C AbbVie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Astra Zeneca, K36, Sanofi, ArcellX, Beigene

A AbbVie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Astra Zeneca, K36, Sanofi, ArcellX, Beigene, Regeneron



The 10th World Congress on Controversies in Multiple Myeloma (COMy)
May 23-26, 2024 - Paris, France & Online
<https://comylive.cme-congresses.com/>

R AbbVie, Amgen, Allogene, Astra Zeneca, BMS, Carsgen, GSK, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron

Alessandra Larocca, Italy

H Janssen, BMS, Sanofi, GSK

A Janssen, GSK

Xavier Leleu, France

Nothing to declare

Lisa Beatrice Leypoldt, Germany

H AbbVie, Janssen, BMS/Celgene, Pfizer, Sanofi

A GSK, Sanofi, Janssen

R AbbVie GSK

Sagar Lonial, USA

C,A Novartis, BMS, Amgen, Takeda, GSK, Celgene, Janssen, AbbVie, Genentech, Pfizer, Regeneron

R Novartis, Janssen, Novartis

O *Board of directors with stock*: TG Therapeutics

Heinz Ludwig, Austria

Nothing to declare

Florent Malard, France

H Therakos/Mallinckrodt, BMS, MSD, Sanofi, Novartis, Astra Zeneca, Jazz

Salomon Manier, France

C AbbVie, Adaptive, Amgen, Celgene/BMS, GSK, Janssen, Novartis, Oncoceptides, Pfizer, Regeneron, Roche, Sanofi, Takeda

Giampaolo Merlini, Italy

Nothing to declare

Hira Mian, Canada

H Janssen, Sanofi, Pfizer, BMS, Takeda, Focus, Amgen, AbbVie

Philippe Moreau, France

H, A Celgene, BMS, Janssen, Amgen, Takeda, AbbVie, Sanofi, Pfizer

Nikhil Munshi, USA

C AbbVie, Adaptive, Amgen, BMS, GSK, Janssen, Karyopharm, Legend, Novartis, Oncoceptides, Pfizer, Takeda

Paola Neri, Canada

H BMS, Janssen, Sanofi, Pfizer, Amgen

C BMS, Janssen, Sanofi, Pfizer

Enrique Ocio, Spain

H Janssen, BMS, Sanofi, GSK, Pfizer, Regeneron, Takeda, Amgen, Oncoceptides

A Janssen, BMS, Sanofi, GSK, Pfizer, AbbVie, Menarini, Oncoceptides, Takeda, Amgen, Karyopharm,

R GSK, Oncoceptides

Bruno Paiva, Spain

H Adaptive, Amgen, Becton Dickinson, BMS, GSK, Janssen, Sanofi, Takeda

C BMS, GSK, Janssen, Roche, Sanofi, Takeda



The 10th World Congress on Controversies in Multiple Myeloma (COMy)

May 23-26, 2024 - Paris, France & Online

<https://comylive.cme-congresses.com/>

A BMS, GSK, Janssen, Roche
R Amgen, Beigene, Becton Dickinson, BMS, GSK, Roche, Sanofi

Aurore Perrot, France

H AbbVie, Amgen, BMS, Janssen, GSK, Pfizer, Sanofi, Takeda
C AbbVie, BMS, Janssen, Pfizer, Sanofi
A AbbVie, Amgen, BMS, Janssen, Pfizer, Sanofi
R BMS, Sanofi, Takeda

Noemi Puig, Spain

H The Binding Site

Paul Richardson, USA

C Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK
R Oncopeptides, Celgene/BMS, Karyopharm, Takeda

Laura Rosiñol Dachs, Spain

H Janssen, BMS, Amgen, Takeda, GSK, Sanofi
A Janssen, BMS, Amgen, Takeda, GSK, Sanofi, Menarini

Fredrik Schjesvold, Norway

H Amgen, BMS, Takeda, AbbVie, Janssen, Oncopeptides, Sanofi, GSK, Menarini
A GSK, Takeda, BMS, Janssen, Oncopeptides, Sanofi, XNK Therapeutics, Galapagos, Pfizer
R Circio

Pieter Sonneveld, Netherlands

A Amgen, BMS, Celgene, Janssen, Karyopharm, Pfizer
R Amgen, BMS, Celgene, Janssen, Karyopharm

Evangelos Terpos, Greece

H, R Amgen

Cyrille Touzeau, France

H,C,A Janssen, AbbVie, Pfizer, Takeda, BMS, Sanofi, Amgen
R Sanofi, GSK

Steven Treon, USA

C BeiGene, Janssen
A BeiGene

Niels van de Donk, Netherlands

A Janssen, Amgen, Celgene, BMS, Takeda, Roche, Novartis, Bayer, Adaptive, Pfizer, AbbVie, Servier
R Janssen, Amgen, Celgene, Novartis, Cellectis, BMS

Elena Zamagni, Italy

A BMS, Sanofi, Janssen, Pfizer, Oncopeptides

Sonja Zweegman, Netherlands

A Janssen, BMS, Sanofi, Oncopeptides
R Janssen, Takeda